IL95265A0 - Renin inhibiting peptides,their preparation and pharmaceutical compositions containing them - Google Patents

Renin inhibiting peptides,their preparation and pharmaceutical compositions containing them

Info

Publication number
IL95265A0
IL95265A0 IL95265A IL9526590A IL95265A0 IL 95265 A0 IL95265 A0 IL 95265A0 IL 95265 A IL95265 A IL 95265A IL 9526590 A IL9526590 A IL 9526590A IL 95265 A0 IL95265 A0 IL 95265A0
Authority
IL
Israel
Prior art keywords
preparation
pharmaceutical compositions
compositions containing
inhibiting peptides
renin inhibiting
Prior art date
Application number
IL95265A
Other languages
English (en)
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL95265A0 publication Critical patent/IL95265A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/26—Oxygen atoms attached in position 2 with hetero atoms or acyl radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
IL95265A 1989-08-05 1990-08-02 Renin inhibiting peptides,their preparation and pharmaceutical compositions containing them IL95265A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3926021 1989-08-05
DE4004820A DE4004820A1 (de) 1989-08-05 1990-02-16 Renininhibitoren, verfahren zur herstellung und ihre verwendung in arzneimitteln

Publications (1)

Publication Number Publication Date
IL95265A0 true IL95265A0 (en) 1991-06-30

Family

ID=25883767

Family Applications (1)

Application Number Title Priority Date Filing Date
IL95265A IL95265A0 (en) 1989-08-05 1990-08-02 Renin inhibiting peptides,their preparation and pharmaceutical compositions containing them

Country Status (12)

Country Link
US (1) US5095006A (xx)
EP (1) EP0412350A3 (xx)
JP (1) JPH0381256A (xx)
KR (1) KR910004657A (xx)
AU (1) AU6019390A (xx)
CA (1) CA2022692A1 (xx)
DE (1) DE4004820A1 (xx)
FI (1) FI903845A0 (xx)
HU (1) HUT54386A (xx)
IE (1) IE902815A1 (xx)
IL (1) IL95265A0 (xx)
PT (1) PT94913A (xx)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68916271T2 (de) * 1988-01-26 1995-02-23 Sankyo Co Renin inhibierende Polypeptide, ihre Herstellung und Anwendung.
AU2194492A (en) * 1991-07-02 1993-02-11 Sandoz Ltd. 4-amino-3-hydroxycarboxylic acid derivatives
TW217410B (xx) * 1992-04-01 1993-12-11 Ciba Geigy
US5972990A (en) * 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
DE4215874A1 (de) * 1992-05-14 1993-11-18 Bayer Ag Dithiolanylglycinhaltige HIV-Proteaseinhibitoren vom Hydroxyethylenisostertyp
JP2003509478A (ja) * 1999-09-21 2003-03-11 エモリー・ユニバーシティ 血小板関連障害を処置する方法および組成物
AU2002230848B2 (en) 2000-12-14 2008-01-24 The Brigham And Women's Hospital, Inc. Inflammatory markers for detection and prevention of diabetes mellitus
US7297553B2 (en) * 2002-05-28 2007-11-20 Nanosphere, Inc. Method for attachment of silylated molecules to glass surfaces
HUE027779T2 (en) 2002-05-09 2016-11-28 Brigham & Womens Hospital Inc 1L1RL-1 is a marker of cardiovascular disease
US7273616B2 (en) * 2002-05-10 2007-09-25 The Trustees Of Columbia University In The City Of New York Genetically engineered cell lines and systems for propagating Varicella zoster virus and methods of use thereof
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
EP1667643A4 (en) * 2003-08-28 2008-03-05 Nitromed Inc NITROSIS AND NITROSYL CARDIOVASCULAR COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
HUE027546T2 (en) 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as cell necrosis inhibitors
AU2004296829A1 (en) 2003-12-05 2005-06-23 The Cleveland Clinic Foundation Risk markers for cardiovascular disease
US20090131342A1 (en) * 2004-01-22 2009-05-21 Nitromed, Inc. Nitrosated and/or nitrosylated compounds, compositions and methods of use
WO2005087752A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
JP2007528404A (ja) * 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換された尿素およびカルバメート、フェナシル−２−ヒドロキシ−３−ジアミノアルカン、ならびにベンズアミド−２−ヒドロキシ−３−ジアミノアルカン系のアスパラギン酸プロテアーゼ阻害薬
WO2005087751A2 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
US7803838B2 (en) * 2004-06-04 2010-09-28 Forest Laboratories Holdings Limited Compositions comprising nebivolol
WO2006010094A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals, Inc. Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
CA2573138A1 (en) * 2004-07-09 2006-01-26 Elan Pharmaceuticals Inc. Oxime derivative substituted hydroxyethylamine aspartyl protease inhibitors
EP1802574A2 (en) * 2004-08-27 2007-07-04 Elan Pharmaceuticals Inc. Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
EP1789388A2 (en) * 2004-08-27 2007-05-30 Elan Pharmaceuticals, Inc. Methods of treatment of amyloidosis using substituted ethanolcyclicamine aspartyl protease inhibitors
US8067464B2 (en) 2004-10-04 2011-11-29 Nitromed, Inc. Compositions and methods using apocynin compounds and nitric oxide donors
CA2624601C (en) 2004-10-06 2018-07-03 The Brigham And Women's Hospital, Inc. Relevance of achieved levels of markers of systemic inflammation following treatment
AU2005306629A1 (en) * 2004-11-15 2006-05-26 Nicox S.A. Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use
WO2006078995A1 (en) * 2005-01-21 2006-07-27 Nitromed, Inc. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
EP1848424B1 (en) * 2005-01-31 2017-04-05 Mylan Laboratories, Inc Pharmaceutical composition comprising hydroxylated nebivolol
JP2008530226A (ja) * 2005-02-16 2008-08-07 ニトロメッド インコーポレーティッド 抗微生物化合物の有機酸化窒素供与体塩、組成物、および使用法
WO2006093864A1 (en) * 2005-02-28 2006-09-08 Nitromed, Inc. Cardiovascular compounds comprising nitric oxide enhancing groups, compositions and methods of use
WO2006099058A2 (en) * 2005-03-09 2006-09-21 Nitromed, Inc. Organic nitric oxide enhancing salts of angiotensin ii antagonists, compositions and methods of use
EP1982711A1 (en) 2005-05-31 2008-10-22 Mylan Laboratories, Inc Compositions comprsing nebivolol
WO2007016677A2 (en) 2005-08-02 2007-02-08 Nitromed, Inc. Nitric oxide enhancing antimicrobial compounds, compositions and methods of use
EP1942909A4 (en) * 2005-10-04 2010-01-06 Nitromed Inc METHODS OF TREATING RESPIRATORY DISORDERS
US8119358B2 (en) 2005-10-11 2012-02-21 Tethys Bioscience, Inc. Diabetes-related biomarkers and methods of use thereof
WO2007047305A1 (en) * 2005-10-12 2007-04-26 Elan Pharmaceuticals, Inc. Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
EP1937638A1 (en) * 2005-10-12 2008-07-02 Elan Pharmaceuticals Inc. Methods of treating amyloidosis using aryl-cyclopropyl derivative aspartyl protease inhibitors
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
WO2007075541A2 (en) * 2005-12-20 2007-07-05 Nitromed, Inc. Nitric oxide enhancing glutamic acid compounds, compositions and methods of use
WO2007075542A2 (en) * 2005-12-22 2007-07-05 Nitromed, Inc. Nitric oxide enhancing pyruvate compounds, compositions and methods of use
US20080057590A1 (en) * 2006-06-07 2008-03-06 Mickey Urdea Markers associated with arteriovascular events and methods of use thereof
TW200849035A (en) 2007-04-18 2008-12-16 Tethys Bioscience Inc Diabetes-related biomarkers and methods of use thereof
JP2013518618A (ja) 2010-02-01 2013-05-23 ザ・ホスピタル・フォー・シック・チルドレン 再狭窄を治療および予防するための遠隔虚血コンディショニング
SG10201502031XA (en) 2010-03-31 2015-05-28 Hospital For Sick Children Use of remote ischemic conditioning to improve outcome after myocardial infarction
JP6377054B2 (ja) 2012-05-11 2018-08-22 リセット セラピューティークス， インコーポレイテッド クリプトクロム調節薬としてのカルバゾール含有スルホンアミド
AU2013296803B2 (en) 2012-08-01 2018-03-08 Eric Ostertag Free flowing, frozen compositions comprising a therapeutic agent
WO2014145022A1 (en) 2013-03-15 2014-09-18 President And Fellows Of Harvard College Hybrid necroptosis inhibitors
TWI690521B (zh) 2014-04-07 2020-04-11 美商同步製藥公司 作為隱花色素調節劑之含有咔唑之醯胺類、胺基甲酸酯類及脲類
CN109563144B (zh) 2016-06-01 2023-03-28 雅斯娜 化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1164240B (it) * 1983-05-25 1987-04-08 Anic Spa Decapeptide parzialmente retro-invertito inibitore specifico della renina con elevata resistenza alla idrolisi enzimatica
IT1164239B (it) * 1983-05-25 1987-04-08 Anic Spa Un retro-inverso analogo del decapeptide (5-14)dell'angiotensinogeno equino inibitore specifico della renina con elevata resistenza all'idrolisi enzimatica

Also Published As

Publication number Publication date
CA2022692A1 (en) 1991-02-06
FI903845A0 (fi) 1990-08-02
EP0412350A2 (de) 1991-02-13
HUT54386A (en) 1991-02-28
EP0412350A3 (en) 1992-03-25
IE902815A1 (en) 1991-02-27
PT94913A (pt) 1991-04-18
JPH0381256A (ja) 1991-04-05
AU6019390A (en) 1991-02-07
DE4004820A1 (de) 1991-04-25
US5095006A (en) 1992-03-10
KR910004657A (ko) 1991-03-29

Similar Documents

Publication Publication Date Title
IL95265A0 (en) Renin inhibiting peptides,their preparation and pharmaceutical compositions containing them
IL103612A0 (en) Peptides,their preparation and pharmaceutical compositions containing them
IL95155A0 (en) 1h-indazole-3-carboxamides,their preparation and pharmaceutical compositions containing them
IL95640A0 (en) 1-cycloalkylpiperidines,their preparation and pharmaceutical compositions containing them
IL85136A0 (en) Peptide derivatives,their preparation and pharmaceutical compositions containing them
IL106326A0 (en) Peptides, their production and pharmaceutical compositions containing them
IL106600A (en) Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
IL94556A0 (en) Hydroxypropylamines,their preparation and pharmaceutical compositions containing them
IL101380A0 (en) Bis-naphthalimides,their preparation and pharmaceutical compositions containing them
IL95622A0 (en) Condensed diazepinones,their preparation and pharmaceutical compositions containing them
IL81833A (en) Renin inhibitory peptides,their preparation and pharmaceutical compositions containing them
IL111011A0 (en) Bisbenzimidazole compounds, their preparation and pharmaceutical compositions containing them
IL90753A0 (en) Azacyclic compounds,their preparation and pharmaceutical compositions containing them
IL108624A0 (en) Pseudopeptides, their preparation and pharmaceutical compositions containing them
IL90315A0 (en) Imidazoquinoxaline compounds,their preparation and pharmaceutical compositions containing them
IL90590A0 (en) Condensed diazepinones,their preparation and pharmaceutical compositions containing them
IL96216A0 (en) Peptide derivatives,their preparation and pharmaceutical compositions containing them
IL91402A0 (en) Aminomethyl peptides,their preparation and pharmaceutical compositions containing them
IL102666A0 (en) Quinolin-2-yl-methoxybenzyl-hydroxyureas,their preparation and pharmaceutical compositions containing them
IL103926A0 (en) Quinolylmethoxyphenyl-acetamides,their preparation and pharmaceutical compositions containing them
IL111216A0 (en) Heteroarylpiperidines, their preparation and pharmaceutical compositions containing them
IL104525A0 (en) 4-cinnolinyl-and 4-naphthyridinyl-dihydropyridines,their preparation and pharmaceutical compositions containing them
IL104424A0 (en) Pyrrolylbenzodiazepinones,their preparation and pharmaceutical compositions containing them
IL92441A (en) Imidazole containing peptides, their preparation and pharmaceutical compositions containing them
IL95563A0 (en) Substituted amino-pyridines,their preparation and pharmaceutical compositions containing them